Relation of Helicobacter Pylori in Prediabetic Patients

Status Not yet recruiting

Clinical Trial Summary

The primary objective of this study is to : find the relation between H.pylori infection and pre-diabetic patients with lipid profile . Specifically, the study aims to: 1. affect of H.pylori infection in pre-diabetic patients 2. realation between Pre-diabetic patient and lipid profile 3. Risk factor of H.pylori infection in pre-diabetic patients D)HbA1C test measures your average blood sugar level over the past 2 or 3 months. e)Fasting Blood Sugar Test. f) the IgG antibody of h.pylori.

Clinical Trial Description

Pre-diabetic state is aphase of impaired glucose tolerance 2 hours Postprandial Glucose (PG) in 75 g oral glucose tolerance test 140 mg/dL-199 mg/dL and/or impaired fasting glucose 100 mg/dL-125 mg/dL and/or HbA1c 5.7-6.4% [5]. Pre-diabetes is pathophysiologically similar to Type II Diabetes with basic defect being insulin resistance and early beta cell failure. The amplitude of large pulses and the rapid oscillations of insulin secretion are lost in pre-diabetes. In pre-diabetes, the glycaemic excursions are usually lower than normaland there is a delay and prolongation in the second phase of insulin secretion [6]. Recent studies have shown that colonisation with H.pylori is associated with increased development of diabetes mellitus [7-11]. A step towards identifying treatable causes of diabetes mellitus will aid the medical health system in developing new strategies in preventing the progression of pre-diabetes to overt diabetes mellitus .Dyslipidemia is a complex disease and a major risk factor foradverse cardiovascular events [12]. High levels of Low Density Lipoproteins (LDL) and low levels of High Density Lipoprotein (HDL) are associated with increased incidence of stoke and myocardial infarction [13]. dyslipidemia also plays a major role in macrovascular complications of Diabetes [14]. There is increasing evidence for the role of H.pylori infection in the initiation, development or persistence of atherosclerosis and coronary heart disease [15,16]. Therefore, exploring the role of treatable causes of dyslipidemia like H.pylorimay help in preventing the progression of dyslipidemia and its adverse effects.The present study aimed to assess the possible role of H.pylori infection on diabetic profile and lipid profile in pre-diabetic patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06176547
Study type	Observational
Source	Assiut University
Contact	Khalid Mahmmoud
Phone	01221844481
Email	k.mahmmoud22@gmail.com
Status	Not yet recruiting
Phase
Start date	March 1, 2024
Completion date	April 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04550858` - h.Pylori Ttt With Rebamipide
Completed	`NCT03650543` - Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication	Phase 4
Recruiting	`NCT04022109` - Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
Completed	`NCT05857163` - Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection	Phase 3
Not yet recruiting	`NCT06425393` - Intrafamilial Helicobacter Pylori Infection in Hong Kong	N/A
Not yet recruiting	`NCT05882968` - Prevalence of H.Pylori in CKD Patients
Completed	`NCT03837210` - Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen	Phase 2/Phase 3
Completed	`NCT02332213` - Volatile Markers in Digestive Cancer
Completed	`NCT03592069` - Concomitant Versus Hybrid Regimen for H. Pylori Eradication	Phase 4
Completed	`NCT06315478` - Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians	Phase 4
Not yet recruiting	`NCT05951998` - Frequency of h.Pylori in Children With Dyspeptic Symptoms
Recruiting	`NCT06431737` - Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.